)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
While Illumina is reducing its workforce in the US, it plans to hire in India, where it currently employs only 30 people
Facility in Maharashtra has annual production capacity of 130,000 units
IT services, a growth driver, showed a revenue and profit slowdown, ranking third in net profit after banks and oil firms
2023 likely to be a record year for luxury car sales
The Mahindra OJA 27 HP tractor will be priced at Rs 5.64 lakh, while the OJA 40 HP tractor will cost Rs 7.35 lakh - priced competitively against its competition
Sachit Kanwar moves court against father Surinder over settlement
IMA felt that if the Centre is serious about implementing generic drugs, then it should not give licences to branded drugs at all, and at the same time ensure the quality of generic drugs
"Power thus shifts to chemists instead of doctors. Whichever company offers better incentives, the chemist would prefer it," the industry feared
Industry insiders feel this is a step towards implementing and codifying the Uniform Code of Pharmaceutical Marketing Practices
Specific provision for recall of drugs and devices; penal provisions for substandard drugs
BBL is actively working on raising funds from private equity investors to retire part of the $1.4 billion debt that was incurred due to the acquisition
UV production experienced a 28.5 per cent growth in July, indicating a gradual resolution of the semiconductor crisis and improvements in the supply chain
According to sources, DCGI has convened a meeting in Delhi on August 10 to discuss matters related to the draft New Drugs, Medical Devices and Cosmetics Bill, 2023
The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane
The diagnostic player has also taken price hikes in the range of 4-5 percent in the last three years
M&M Board had approved a stake buy of up to 4.5 per cent in RBL Bank
The board has recommended a dividend of Rs 16.25 per share
Seek a separate 'Medical Devices Act' distinct from the drug regulations Bill
Sun Pharma's stock ended flat at Rs 1140.85 on the BSE
Singapore investment firm to hold 1.49-2.97% stake in EV business